FDA gives Ultomiris accelerated approval for IgA nephropathy

+9.3strongly positive

+9.3

Headlines18

Outlets18

Days322 October – 24 October

Outlets report the FDA accelerated approval of Ultomiris in IgAN, its fifth indication.

Tone by day

Average of each day's headlines, −10 to +10.

Source: MarketFrame news analysis

Tone by day. Average of each day's headlines, −10 to +10. Source: MarketFrame news analysis
day	Average tone
22 Oct	9.6
23 Oct	8.9
24 Oct	10.0

The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

The 10 outlets with the most impact on the tone

Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.

Source: MarketFrame news analysis

The 10 outlets with the most impact on the tone. Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone. Source: MarketFrame news analysis
outlet	Average tone
Traders Union	10.0
Medical Dialogues	10.0
Reuters	10.0
Mezha.net	10.0
Investing.com UK	9.5
Investing.com	9.5
Pharmaceutical Technology	9.2
Sharecast	9.2
insights.citeline.com	9.2
FirstWord Pharma	9.2

Outlet	Headlines	Average tone
Traders Union	1	+10.0
Medical Dialogues	1	+10.0
Reuters	1	+10.0
Mezha.net	1	+10.0
Investing.com UK	1	+9.5
Investing.com	1	+9.5
Pharmaceutical Technology	1	+9.2
Sharecast	1	+9.2
insights.citeline.com	1	+9.2
FirstWord Pharma	1	+9.2

All 18 outlets

Outlet	Headlines	Average tone
Fierce Pharma	1	+9.2
Zacks Investment Research	1	+9.2
Indian Pharma Post	1	+9.2
TipRanks	1	+9.2
Kalkine Media	1	+8.3
AllSci	1	+8.3
lifesciencesweden.se	1	+8.3
News Ghana	1	+8.3

One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.

Tone	What the article reported, and why it scored that way	Source
+10.0	Shares rise after approvals for Ultomiris and Zegfrovy.	Traders Union (opens the article) ↗
+10.0	FDA clears Ultomiris for a rare kidney condition in the US.	Medical Dialogues (opens the article) ↗

AstraZeneca on 24 October

Tone	What the article reported, and why it scored that way	Source
+9.2	Ultomiris receives an additional US approved indication	Pharmaceutical Technology (opens the article) ↗
+9.2	Ultomiris is granted US approval under the accelerated route	Sharecast (opens the article) ↗
+9.2	Ultomiris gains IgAN accelerated approval	insights.citeline.com (opens the article) ↗
+9.2	Fifth Ultomiris indication approved by FDA	FirstWord Pharma (opens the article) ↗
+9.2	Fifth rare disease indication for Ultomiris	Fierce Pharma (opens the article) ↗
+9.2	FDA accelerated nod for Ultomiris in IgAN	Zacks Investment Research (opens the article) ↗
+9.2	FDA accelerated approval for Ultomiris in IgAN	Indian Pharma Post (opens the article) ↗
+8.3	New Ultomiris approval seen as positive	Kalkine Media (opens the article) ↗

3 more headlines that day

Tone	What the article reported, and why it scored that way	Source
+8.3	FDA grants accelerated approval for lowering proteinuria in IgAN	AllSci (opens the article) ↗
+8.3	FDA grants a further approval covering a serious kidney condition	lifesciencesweden.se (opens the article) ↗
+8.3	Ultomiris receives FDA clearance to treat a rare kidney disease	News Ghana (opens the article) ↗

AstraZeneca on 23 October

Tone	What the article reported, and why it scored that way	Source
+10.0	FDA approval for adults with an uncommon kidney disease.	Reuters (opens the article) ↗
+10.0	Ultomiris gets FDA approval to treat a rare kidney disease.	Mezha.net (opens the article) ↗
+9.5	Drug for a rare kidney disease receives FDA approval.	Investing.com UK (opens the article) ↗
+9.5	FDA gives the go-ahead to a drug for a rare kidney disease.	Investing.com (opens the article) ↗
+9.2	Ultomiris approval to reduce proteinuria.	TipRanks (opens the article) ↗

AstraZeneca on 22 October

A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

The story

Tone by day

How each outlet covered it · 18 outlets

The 10 outlets with the most impact on the tone

Day by day · 3 days, strongest headlines first

Follow by email